IL6 and congenital rubella syndrome: In line with these findings, our data further confirm this view and suggest HMGB1 serves as a predictive biomarker and attractive therapeutic target for CRS since 7/10 patients who received CAR-T cells induce high levels of HMGB1, which preceded IL-6 release (Fig. 1).